SG102686A1 - Aryl fused azapolycyclic compounds - Google Patents
Aryl fused azapolycyclic compoundsInfo
- Publication number
- SG102686A1 SG102686A1 SG200203917A SG200203917A SG102686A1 SG 102686 A1 SG102686 A1 SG 102686A1 SG 200203917 A SG200203917 A SG 200203917A SG 200203917 A SG200203917 A SG 200203917A SG 102686 A1 SG102686 A1 SG 102686A1
- Authority
- SG
- Singapore
- Prior art keywords
- aryl fused
- fused azapolycyclic
- azapolycyclic compounds
- compounds
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7024597P | 1997-12-31 | 1997-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG102686A1 true SG102686A1 (en) | 2004-03-26 |
Family
ID=22094096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200203917A SG102686A1 (en) | 1997-12-31 | 1998-11-13 | Aryl fused azapolycyclic compounds |
Country Status (52)
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
EA003190B1 (en) * | 1997-12-31 | 2003-02-27 | Пфайзер Продактс Инк. | Aryl fused azapolycyclic compounds |
DE60040293D1 (en) | 1999-07-28 | 2008-10-30 | Univ R | USE OF NICOTIN IN THE ANGIOGENESIS AND THE VASCULOSIS |
US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
US20020010192A1 (en) * | 2000-06-02 | 2002-01-24 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
JP2004527545A (en) * | 2001-04-20 | 2004-09-09 | ファイザー・プロダクツ・インク | Method for preparing 1,3-substituted indene and aryl-fused azapolycyclic compounds |
DZ3503A1 (en) * | 2001-05-14 | 2002-11-21 | ||
IL157933A0 (en) * | 2001-05-14 | 2004-03-28 | Pfizer Prod Inc | Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9] -hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
WO2003045394A1 (en) * | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
WO2003045967A1 (en) | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
DE60218885T2 (en) * | 2001-11-30 | 2008-01-17 | Pfizer Products Inc., Groton | Oral pharmaceutical dosage forms of 5,8,14-triazatetra-cyclo- (10.3.1.0 (2,11) .0 (4,9) -hexadeca-2 (11), 3,5,7,9-pentaene with controlled release |
US8143210B2 (en) | 2002-02-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
EP2364718B1 (en) | 2002-02-14 | 2016-07-06 | The Board of Trustees of the Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
US7320788B2 (en) * | 2002-02-14 | 2008-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
US7462688B2 (en) * | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
US7202216B2 (en) * | 2002-05-14 | 2007-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
EP1507549A4 (en) * | 2002-05-14 | 2009-07-01 | Univ Leland Stanford Junior | Drug therapy for celiac sprue |
US7265093B2 (en) * | 2002-05-14 | 2007-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
DK1563300T3 (en) | 2002-11-20 | 2012-07-23 | Univ Leland Stanford Junior | Diagnostic procedure for celiac disease |
JP2006506432A (en) * | 2002-11-20 | 2006-02-23 | ファイザー・プロダクツ・インク | Method for producing indane-1,3-dicarboxylic acid |
RU2284319C2 (en) * | 2002-11-25 | 2006-09-27 | Пфайзер Продактс Инк. | Improved method for preparing 1,3-substituted indenes |
MXPA05007565A (en) * | 2003-01-15 | 2005-09-21 | Pfizer Prod Inc | Process for the preparation of aryl fused polycyclic lactams. |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20040224963A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
EP1633358A1 (en) * | 2003-05-20 | 2006-03-15 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
BRPI0410613A (en) * | 2003-06-04 | 2006-06-20 | Pfizer Prod Inc | preparation of substituted quinoxaline from dianlin with 2,3-dihydroxy-1,4-dioxane |
MXPA06000785A (en) * | 2003-07-21 | 2006-04-18 | Pfizer Prod Inc | Nicotine addiction reducing heteroaryl fused azapolycyclic compounds. |
MXPA06000892A (en) * | 2003-07-21 | 2006-03-30 | Pfizer Prod Inc | Aryl fused azapolycyclic compounds. |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US7579313B2 (en) | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
US7563864B2 (en) * | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
US7628985B2 (en) * | 2004-04-26 | 2009-12-08 | The Board Of Regents Of The Leland Stanford Junior University | Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis |
US7534426B2 (en) * | 2004-04-26 | 2009-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Glutenase enzyme assays |
WO2006006071A1 (en) * | 2004-07-07 | 2006-01-19 | Pfizer Products Inc. | Resolution of an aryl-fused azapolycyclic compound |
US7766018B2 (en) * | 2004-09-30 | 2010-08-03 | Smoke-Break, Inc. | Device and composition for reducing the incidence of tobacco smoking |
JP2008531540A (en) * | 2005-02-24 | 2008-08-14 | ファイザー・プロダクツ・インク | Preparation of high purity substituted quinoxaline |
US20060211649A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of cytisine for enhancing physical performance |
US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
RU2008138532A (en) * | 2006-03-27 | 2010-04-10 | Пфайзер Продактс Инк. (Us) | VARENIKLIN STANDARDS AND CONTROL OF IMPURITIES |
WO2007122510A2 (en) * | 2006-04-24 | 2007-11-01 | Pfizer Products Inc. | Asymmetric membranes for drug delivery devices |
EP2255848A3 (en) | 2006-09-04 | 2011-04-06 | NeuroSearch AS | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
CA2666327A1 (en) * | 2006-11-09 | 2008-05-22 | Pfizer Products Inc. | Polymorphs of nicotinic intermediates |
US8778338B2 (en) * | 2007-03-16 | 2014-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Combination enzyme therapy for digestion of dietary gluten |
WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
WO2009101185A2 (en) * | 2008-02-15 | 2009-08-20 | Medichem, S.A. | A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE |
US20090215787A1 (en) * | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
WO2009146031A1 (en) * | 2008-03-31 | 2009-12-03 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
US8039620B2 (en) * | 2008-05-22 | 2011-10-18 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate |
US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
EP2334679A1 (en) * | 2008-09-01 | 2011-06-22 | Actavis Group PTC EHF | Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof |
EP2204369A1 (en) | 2008-12-22 | 2010-07-07 | Medichem, S.A. | Process for preparing varenicline and intermediates for use therein |
BRPI1008020A2 (en) | 2009-02-11 | 2016-03-15 | Sunovion Pharmaceuticals Inc | histamine h3 antagonists and inverse agonists and methods of using them |
EP2440187A2 (en) | 2009-06-10 | 2012-04-18 | Actavis Group PTC ehf. | Amorphous varenicline tartrate co-precipitates |
EP2438054A1 (en) * | 2009-06-22 | 2012-04-11 | Teva Pharmaceutical Industries Ltd. | Solid states forms of varenicline salts and processes for preparation thereof |
WO2011031818A2 (en) * | 2009-09-11 | 2011-03-17 | Sepracor Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
EP2545054A1 (en) | 2010-03-09 | 2013-01-16 | Actavis Group Ptc Ehf | Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
KR101109389B1 (en) * | 2010-04-30 | 2012-01-30 | 삼성전기주식회사 | A printed circuit board and a method of manufacturing the same |
WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
US20120004239A1 (en) | 2010-06-11 | 2012-01-05 | Medichem, S.A. | Process for Preparing Quinoxaline Derivatives |
AU2012276651A1 (en) | 2011-06-30 | 2014-02-06 | Toray Industries, Inc. | Antipruritic agent |
ITMI20111413A1 (en) * | 2011-07-28 | 2013-01-29 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF VARENICLINA |
ES2426517B1 (en) | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Method to predict the safety of a drug treatment |
ES2426838B1 (en) | 2012-04-20 | 2014-05-07 | Genetracer Biotech S.L | Method to predict success in quitting tobacco use in response to drug treatment |
CN103570502A (en) * | 2012-07-18 | 2014-02-12 | 上海科胜药物研发有限公司 | Preparation method for varenicline intermediate |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
CN103992272B (en) * | 2014-06-09 | 2016-05-11 | 安徽省逸欣铭医药科技有限公司 | A kind of pentazocine hydrochloride ester, Its Preparation Method And Use |
KR20160126697A (en) | 2015-04-24 | 2016-11-02 | 한미정밀화학주식회사 | Novel crystalline varenicline oxalate hydrate, preparation method thereof, and pharmaceutical composition comprising same |
KR20160143407A (en) | 2015-06-05 | 2016-12-14 | 한미정밀화학주식회사 | Novel varenicline mucate, crystalline form thereof, and method of preparation thereof |
KR101724301B1 (en) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | Novel crystal form I of varenicline salicylate and its preparing method |
CN106674194B (en) * | 2016-12-14 | 2019-03-05 | 山东省联合农药工业有限公司 | A kind of nicotinic insecticide of structure novel and its preparation method and application |
JP7137850B2 (en) | 2017-03-03 | 2022-09-15 | シーティーシー バイオ インク | Formulation for buccal administration comprising an inclusion complex of varenicline or a pharmaceutically acceptable salt thereof |
KR102463733B1 (en) | 2017-06-30 | 2022-11-04 | 한미약품 주식회사 | Pharmaceutical composition comprising Varenicline Oxalate with improved content uniformity and stability |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
KR20200034293A (en) | 2018-09-21 | 2020-03-31 | 한미약품 주식회사 | Varenicline formulation for controlled-release |
EP4142734A1 (en) | 2020-04-28 | 2023-03-08 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
CN113956255A (en) * | 2020-07-20 | 2022-01-21 | 威智医药有限公司 | Preparation method of varenicline intermediate, varenicline and salt thereof |
US11040983B1 (en) | 2020-08-14 | 2021-06-22 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
WO2022035434A1 (en) | 2020-08-14 | 2022-02-17 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
WO2022147189A1 (en) * | 2020-12-30 | 2022-07-07 | Antares Pharma, Inc. | Varenicline prodrugs |
WO2022222019A1 (en) * | 2021-04-20 | 2022-10-27 | Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd | Total synthesis of varenicline |
CN113277993B (en) * | 2021-06-06 | 2023-07-21 | 湖南第一师范学院 | Synthesis method of Tafamidis and derivatives thereof |
WO2023275413A2 (en) | 2021-12-23 | 2023-01-05 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
US11602537B2 (en) | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
EP4241775A1 (en) | 2022-03-11 | 2023-09-13 | Par Pharmaceutical, Inc. | Tablet comprising varenicline and process of preparation thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3471503A (en) * | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
CH644116A5 (en) * | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | IMIDAZOLE DERIVATIVES. |
EP0853621A1 (en) † | 1995-09-22 | 1998-07-22 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
EA003190B1 (en) * | 1997-12-31 | 2003-02-27 | Пфайзер Продактс Инк. | Aryl fused azapolycyclic compounds |
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
EP0955301A3 (en) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
WO1999055680A1 (en) * | 1998-04-29 | 1999-11-04 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
EP1359152B1 (en) * | 1999-01-29 | 2008-05-07 | Abbott Laboratories | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
FR2788982B1 (en) * | 1999-02-02 | 2002-08-02 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE AND THEIR APPLICATION IN SMOKING WITHDRAWAL |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
IL157933A0 (en) * | 2001-05-14 | 2004-03-28 | Pfizer Prod Inc | Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9] -hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
DZ3503A1 (en) * | 2001-05-14 | 2002-11-21 | ||
WO2003045394A1 (en) * | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
DE60218885T2 (en) * | 2001-11-30 | 2008-01-17 | Pfizer Products Inc., Groton | Oral pharmaceutical dosage forms of 5,8,14-triazatetra-cyclo- (10.3.1.0 (2,11) .0 (4,9) -hexadeca-2 (11), 3,5,7,9-pentaene with controlled release |
WO2003045967A1 (en) * | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
MXPA06000892A (en) * | 2003-07-21 | 2006-03-30 | Pfizer Prod Inc | Aryl fused azapolycyclic compounds. |
-
1998
- 1998-11-13 EA EA200000592A patent/EA003190B1/en not_active IP Right Cessation
- 1998-11-13 BR BRPI9814592-4A patent/BR9814592B1/en not_active IP Right Cessation
- 1998-11-13 CZ CZ20002438A patent/CZ301925B6/en not_active IP Right Cessation
- 1998-11-13 AT AT98950274T patent/ATE386024T1/en active
- 1998-11-13 KR KR10-2000-7007379A patent/KR100408138B1/en active IP Right Review Request
- 1998-11-13 DK DK98950274T patent/DK1044189T4/en active
- 1998-11-13 EP EP98950274.5A patent/EP1044189B2/en not_active Expired - Lifetime
- 1998-11-13 US US09/402,010 patent/US6410550B1/en not_active Expired - Lifetime
- 1998-11-13 SI SI9830902T patent/SI1044189T2/en unknown
- 1998-11-13 SG SG200203917A patent/SG102686A1/en unknown
- 1998-11-13 TR TR2000/01840T patent/TR200001840T2/en unknown
- 1998-11-13 EP EP05106853A patent/EP1659114A3/en not_active Withdrawn
- 1998-11-13 CN CNB988128195A patent/CN1324013C/en not_active Expired - Lifetime
- 1998-11-13 BR BRPI9816186-5A patent/BR9816186B1/en not_active IP Right Cessation
- 1998-11-13 ME MEP-2008-702A patent/ME00459B/en unknown
- 1998-11-13 UA UA2000063807A patent/UA66825C2/en unknown
- 1998-11-13 HU HU0100949A patent/HU230297B1/en active Protection Beyond IP Right Term
- 1998-11-13 NZ NZ504482A patent/NZ504482A/en not_active IP Right Cessation
- 1998-11-13 ES ES98950274.5T patent/ES2301210T5/en not_active Expired - Lifetime
- 1998-11-13 WO PCT/IB1998/001813 patent/WO1999035131A1/en active IP Right Grant
- 1998-11-13 CN CNA2005100821428A patent/CN1715280A/en active Pending
- 1998-11-13 PT PT98950274T patent/PT1044189E/en unknown
- 1998-11-13 PL PL341824A patent/PL209404B1/en unknown
- 1998-11-13 JP JP2000527532A patent/JP3550359B2/en not_active Expired - Lifetime
- 1998-11-13 AU AU96416/98A patent/AU753389C/en not_active Expired
- 1998-11-13 DE DE69839131.4T patent/DE69839131T3/en not_active Expired - Lifetime
- 1998-11-13 CA CA002316921A patent/CA2316921C/en not_active Expired - Lifetime
- 1998-11-13 RS YUP-403/00A patent/RS50069B/en unknown
- 1998-11-13 SK SK971-2000A patent/SK286886B6/en not_active IP Right Cessation
- 1998-11-13 DE DE122008000038C patent/DE122008000038I1/en active Pending
- 1998-11-13 IL IL13672798A patent/IL136727A0/en active Protection Beyond IP Right Term
- 1998-11-19 HN HN1998000177A patent/HN1998000177A/en unknown
- 1998-11-30 PA PA19988463901A patent/PA8463901A1/en unknown
- 1998-11-30 CO CO98070723A patent/CO4810373A1/en unknown
- 1998-12-15 GT GT199800200AK patent/GT199800200AA/en unknown
- 1998-12-15 GT GT199800200A patent/GT199800200A/en unknown
- 1998-12-17 AP APAP/P/1998/001422A patent/AP1170A/en active
- 1998-12-28 PE PE1998001286A patent/PE20000053A1/en not_active IP Right Cessation
- 1998-12-28 TW TW087121748A patent/TW513412B/en not_active IP Right Cessation
- 1998-12-28 EG EG161298A patent/EG23816A/en active
- 1998-12-29 ZA ZA9811911A patent/ZA9811911B/en unknown
- 1998-12-29 AR ARP980106715A patent/AR017967A1/en active IP Right Grant
- 1998-12-30 DZ DZ980307A patent/DZ2697A1/en active
- 1998-12-30 MA MA25409A patent/MA26589A1/en unknown
- 1998-12-30 TN TNTNSN98237A patent/TNSN98237A1/en unknown
- 1998-12-30 MY MYPI98005949A patent/MY118163A/en unknown
-
1999
- 1999-02-28 SA SA99191123A patent/SA99191123B1/en unknown
-
2000
- 2000-05-26 IS IS5514A patent/IS5514A/en unknown
- 2000-06-12 IL IL136727A patent/IL136727A/en active Protection Beyond IP Right Term
- 2000-06-16 OA OA1200000175A patent/OA11428A/en unknown
- 2000-06-27 BG BG104561A patent/BG65058B1/en unknown
- 2000-06-30 NO NO20003422A patent/NO319115B1/en not_active IP Right Cessation
- 2000-06-30 HR HR20000445A patent/HRP20000445B1/en not_active IP Right Cessation
-
2001
- 2001-04-09 HK HK01102476A patent/HK1031878A1/en not_active IP Right Cessation
-
2002
- 2002-02-13 US US10/075,843 patent/US6887884B2/en not_active Expired - Fee Related
- 2002-02-14 US US10/075,348 patent/US20020072524A1/en not_active Abandoned
- 2002-04-22 US US10/127,267 patent/US6951938B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,278 patent/US6897310B2/en not_active Expired - Lifetime
-
2005
- 2005-06-07 HR HR20050506A patent/HRP20050506A2/en not_active Application Discontinuation
-
2006
- 2006-11-17 NO NO2006016C patent/NO2006016I1/en not_active IP Right Cessation
-
2007
- 2007-07-17 US US11/778,890 patent/US20070275973A1/en not_active Abandoned
-
2008
- 2008-04-14 CY CY20081100397T patent/CY1107391T1/en unknown
- 2008-05-21 LU LU91442C patent/LU91442I2/en unknown
- 2008-06-05 NL NL300355C patent/NL300355I2/en unknown
- 2008-07-03 CY CY200800013C patent/CY2008013I1/en unknown
- 2008-07-21 FR FR08C0039C patent/FR08C0039I2/en active Active
-
2016
- 2016-04-27 HU HUS1600018C patent/HUS1600018I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1600018I1 (en) | Aryl fused azapolycyclic compounds | |
GB9708694D0 (en) | Compounds | |
IL138917A0 (en) | Aryl fused azapolycyclic compounds | |
GB9704522D0 (en) | Compounds | |
GB9716101D0 (en) | Fused heterocyclic compounds | |
HU0500571D0 (en) | Aryl fused azapolycyclic compounds | |
SI1076650T1 (en) | Aryl fused azapolycyclic compounds | |
GB9702978D0 (en) | Compounds | |
GB9706953D0 (en) | Compounds | |
GB9825366D0 (en) | Compounds | |
GB9708802D0 (en) | Compounds | |
GB9708070D0 (en) | Compounds | |
GB9706952D0 (en) | Compounds | |
GB9706110D0 (en) | Compounds | |
GB9705652D0 (en) | Compounds | |
GB9705194D0 (en) | Compounds | |
GB9705189D0 (en) | Compounds | |
GB9705188D0 (en) | Compounds | |
GB9704652D0 (en) | Compounds | |
GB9704648D0 (en) | Compounds | |
GB9704581D0 (en) | Compounds | |
GB9704580D0 (en) | Compounds | |
GB9708071D0 (en) | Compounds | |
GB9707444D0 (en) | Compounds | |
GB9704579D0 (en) | Compounds |